selected publications

• article

  • Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial.  Journal of Rheumatology.  41:1077-1087. 2014-01-01
  • Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-Year results from the AIM trial.  Annals of the Rheumatic Diseases.  70:1826-1830. 2011-01-01
  • Efficacy and safety of different doses and retreatment of rituximab: A randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)).  Annals of the Rheumatic Diseases.  69:1629-1635. 2010-01-01
  • Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.  Journal of the American Society of Nephrology.  20:1103-1112. 2009-01-01
  • Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate.  Arthritis and Rheumatism.  58:953-963. 2008-01-01
  • Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial.  Annals of Internal Medicine.  144:865-876. 2006-01-01